A pharmacist-led opioid de-escalation program after completion of chemoradiotherapy in locally advanced head and neck cancer

Frontiers in Oncology

Oncology

Takao Fujisawa¹  Susumu Okano¹  Tomohiro Enokida¹  Kazue Ito²  Yuri Ueda³  Toshikatsu Kawasaki⁴  Asumi Kaneko⁴  Hayato Kamata⁴  Shinya Suzuki⁴  Chihiro Matsuyama⁵  Ai Horinouchi⁶  Makoto Tahara⁷ 

[1] Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan;Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan;Department of Head and Neck Medical Oncology, Miyagi Cancer Center, Natori, Japan;Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan;Department of Otorhinolaryngology-Head and Neck Surgery, Tokyo Medical University Hospital, Shinjuku-ku, Japan;Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan;Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan;Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan;Department of Pharmacy, South Miyagi Medical Center, Ōgawara, Japan;Department of Pharmacy, South Miyagi Medical Center, Ōgawara, Japan;

关键词: head and neck cancer;    opioid;    tapering;    chemoradiation therapy;    oral mucositis;   

DOI  :  10.3389/fonc.2023.1145323

 received in 2023-01-16, accepted in 2023-08-30,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundPersistent opioid use frequently leads to substantial negative impacts on quality of life, and as the outlook for numerous cancer types continues to improve, these complications become increasingly crucial. It is essential to acknowledge that extended or excessive opioid use may result in adverse effects in patients who completed radiation therapy (RT).MethodsIn this time-series analysis, we compared the outcomes of patients who participated in the pharmacist-led opioid de-escalation (PLODE) program after completing concurrent radiotherapy (CRT) between June 2018 and February 2019 against patients who completed CRT between June 2017 and March 2018 and did not participate in the program.ResultsAmong 61 patients, 16 (26%) used opioids after completing CRT and participated in the PLODE program. Before starting the program, 93 patients completed CRT between June 2017 and March 2018 and 32 (34%) used opioids at CRT completion. These patients were deemed the control group. In the PLODE group, outpatient pharmacist intervention was performed, with 29 total interventions related to opioid use, of which 16 (55%) recommended tapering or discontinuing opioids according to the definition of this program. Patients who participated in the PLODE program discontinued opioids significantly earlier than those in the control group (median time to opioid discontinuation 11 days vs. 24.5 days, p < 0.001). None of the patients in the PLODE group resumed opioid use following discontinuation or escalated opioid dosing due to worsening pain.ConclusionThis study showed the utility of pharmacist-initiated interventions for opioid use in patients with head and neck cancer who had completed CRT.

【 授权许可】

Unknown   
Copyright © 2023 Horinouchi, Enokida, Suzuki, Kamata, Kaneko, Matsuyama, Fujisawa, Ueda, Ito, Okano, Kawasaki and Tahara